trending Market Intelligence /marketintelligence/en/news-insights/trending/61xwlchhpupu2uzely0nlq2 content esgSubNav
In This List

Constellation Pharmaceuticals elects 2 directors to board

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Constellation Pharmaceuticals elects 2 directors to board

Constellation Pharmaceuticals Inc. said its board elected Elizabeth Trehu and Steven Hoerter as directors.

Trehu, who has 16 years of management experience at several biopharmaceutical companies, is currently the chief medical officer of Jounce Therapeutics Inc.

Hoerter is the chief commercial officer of Agios Pharmaceuticals Inc. where he built and leads the team responsible for the commercialization of the company's portfolio of medicines for cancer and rare genetic diseases.

The appointees "bring considerable experience working in the disease areas of myelofibrosis and prostate cancer that is directly relevant to Constellation’s clinical programs," Constellation Pharmaceuticals' President and CEO Jigar Raythatha said in a statement.

Constellation is advancing two lead clinical programs, one for CPI-1205 to treat a type of prostate cancer as well as solid tumors, and another for CPI-0610 — a potential treatment for myelofibrosis.